Skip to content

Summit Therapeutics

US · SMMT #1207 by market cap Listed 2015
9.95 -0.62 -5.87%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Price chart

Pre-market 10.29 -2.65%
After-hours 10.08 +1.31%
Overnight 10.46 -1.04%
18.429.959.952026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on SMMT?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is -29.7% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has risen to 5.3% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days D → E

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 02:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall D+

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability D+

How much profit the business keeps from each dollar of sales and capital.

Gross margin 100.0% Better than 99%
Operating margin -9,018.2% Better than 1%
Net margin -11,174.8% Better than 1%
Return on equity -206.1% Better than 3%
Return on invested capital -200.7% Better than 1%
Momentum D

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -24.4% Better than 24%
6-month return -40.1% Better than 12%
12-month return (ex latest month) -4.4% Better than 29%
Distance below 52-week high 66.0% Better than 8%
Financial Health B+

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 9.9x Better than 93%
Debt to assets 2.8% Better than 85%
Interest coverage -24.5x Better than 9%
Analyst View B+

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 61.5% Better than 38%
Upside to average target 177.1% Better than 93%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -29.68%
1M -38.16%
3M -19.95%
6M -44.38%
YTD -43.11%
1Y -39.51%
3Y +400.00%
5Y +85.98%

Key statistics

Price & volume

Prev close
10.57
Open
10.28
Day range
9.89 - 10.61
Avg price
10.10
Volume
7.22M
Turnover
72.90M
Amplitude
6.81%
52-week range
9.89 - 29.23

Valuation

P/E
-6.91
P/E (TTM)
-9.39
P/B
14.09
EPS
-1.44
Net profit
-1.15B
Net assets
564.63M

Share structure

Market cap
7.96B
Float cap
1.52B
Shares out
799.76M
Float shares
152.29M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2015-03-05
52-week range 0% of range
9.89 29.23

66.0% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-51.22M net over the window

Short interest

Shares short
42.26M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Summit Therapeutics (SMMT)?

Summit Therapeutics last traded at 9.95. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Summit Therapeutics's market cap?

About 7.96B.

What is the P/E ratio of Summit Therapeutics?

The trailing twelve-month P/E is -9.39. The Valuation tab shows it against the stock's own five-year range.

Does Summit Therapeutics pay a dividend?

Summit Therapeutics does not currently pay a regular dividend.

Is Summit Therapeutics a buy according to analysts?

The consensus of 13 analysts is a Buy rating, with an average 12-month price target of 27.57, which implies 177.1% upside from the current price. This is not investment advice.

What is Summit Therapeutics's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Summit Therapeutics a E (Strong Sell). Below its 200-day average and near the bottom of the universe on momentum. Not investment advice.

Quote time 2026-11-20 20:02:25 · For reference only, not investment advice and not tailored to your situation.

Summit Therapeutics discussion 0 comments

Add a comment